Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

EDIT Editas Medicine, Inc. Common Stock
$1.83 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy EDIT stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 173.8M
Enterprise value 31.7M
Trailing PE -0.6215277645323
Forward PE -1.5830395
PEG Ratio 0.0099179962425367
Enterprise to EBITDA -0.283
Enterprise to revenue 0.683
Price to book MRQ 12.569445
Price to sales TTM 3.8093646

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 46.4M
EBITDA -112038000
Diluted EPS TTM -2.35
Total Cash (MRQ) 165.6M
Current ratio (MRQ) 2.864
Operating Cash Flow (TTM) -179616000

EDIT trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent EDIT News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.